These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 456406)

  • 1. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clofibrate pharmacokinetics in chronic renal failure (author's transl)].
    Millart H; Lavaud S; Brunois JP; Lamiable D; Choisy H; Chanard J
    Therapie; 1980; 35(6):705-16. PubMed ID: 7233360
    [No Abstract]   [Full Text] [Related]  

  • 4. Disposition of azapropazone in chronic renal and hepatic failure.
    Breuing KH; Gilfrich HJ; Meinertz T; Wiegand UW; Jähnchen E
    Eur J Clin Pharmacol; 1981; 20(2):147-55. PubMed ID: 7262176
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver.
    Cameron DP; Burger HG; Catt KJ; Gordon E; Watts JM
    Metabolism; 1972 Oct; 21(10):895-904. PubMed ID: 5071956
    [No Abstract]   [Full Text] [Related]  

  • 6. Gemfibrozil absorption and elimination in kidney and liver disease.
    Knauf H; Kölle EU; Mutschler E
    Klin Wochenschr; 1990 Jul; 68(13):692-8. PubMed ID: 2381138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of clofibrate in patients with renal insufficiency.
    Viikari J; Anttila M; Kasanen A
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma half-life of clofibric acid in renal failure.
    Faed EM; McQueen EG
    Br J Clin Pharmacol; 1979 Apr; 7(4):407-10. PubMed ID: 444361
    [No Abstract]   [Full Text] [Related]  

  • 9. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.
    Kawai S; Ichikawa Y; Homma M
    J Clin Endocrinol Metab; 1985 May; 60(5):848-54. PubMed ID: 3980669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cirrhosis and renal failure on the kinetics of clotiazepam.
    Ochs HR; Greenblatt DJ; Knüchel M
    Eur J Clin Pharmacol; 1986; 30(1):89-92. PubMed ID: 2872061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.
    Männistö PT; Tuomisto J; Jounela A; Penttilä O
    Acta Pharmacol Toxicol (Copenh); 1975 Apr; 36(4):353-65. PubMed ID: 1093358
    [No Abstract]   [Full Text] [Related]  

  • 12. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
    Thomson PD; Melmon KL; Richardson JA; Cohn K; Steinbrunn W; Cudihee R; Rowland M
    Ann Intern Med; 1973 Apr; 78(4):499-508. PubMed ID: 4694036
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lower amines in the blood and urine in chronic liver and kidney diseases].
    Martin R; Pohl A; Rotzsch W
    Dtsch Z Verdau Stoffwechselkr; 1977; 37(2):85-8. PubMed ID: 608434
    [No Abstract]   [Full Text] [Related]  

  • 14. [Metabolism of clofibrate in hepatitis and liver cirrhosis].
    Hartlapp JH; Kürten J; Gugler R
    Verh Dtsch Ges Inn Med; 1978; (84):1108-10. PubMed ID: 741896
    [No Abstract]   [Full Text] [Related]  

  • 15. [Aminophenazone half life in patients with chronic liver parenchyma disorders].
    Ackermann E; Renger F; Dökert B; Walther M
    Z Gesamte Inn Med; 1972 Oct; 27(19):849-53. PubMed ID: 4647370
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged elimination of piperacillin in a patient with renal and liver failure.
    Green L; Dick JD; Goldberger SP; Angelopulos CM
    Drug Intell Clin Pharm; 1985 Jun; 19(6):427-9. PubMed ID: 4006736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.
    Thomson PD; Rowland M; Melmon KL
    Am Heart J; 1971 Sep; 82(3):417-21. PubMed ID: 5565429
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of atracurium and its metabolites.
    Ward S; Weatherley BC
    Br J Anaesth; 1986; 58 Suppl 1():6S-10S. PubMed ID: 3754756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
    Krakamp B; Tanswell P; Leidig P; Vogel H; Schmitz R; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):71-3. PubMed ID: 2917592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of intravenous narcotics (barbiturates and fentanyl) anesthesia and intensive care in patients with liver and kidney insufficiency].
    Rietbrock I
    Klin Anasthesiol Intensivther; 1981; 23():59-70. PubMed ID: 7339178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.